We now show that increased NLRP3 inflammasome-mediated IL-1β release from immune cells from humans with severe asthma can be pharmacologically inhibited with MCC950, demonstrating therapeutic potential for inflammasome inhibition in clinical settings. Here, IL1B is linked to asthma.